{"id":"NCT00844519","sponsor":"University of California, San Francisco","briefTitle":"Effect of Maraviroc on Endothelial Function in HIV-Infected Patients","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2012-12","completion":"2014-06","firstPosted":"2009-02-16","resultsPosted":"2014-06-19","lastUpdate":"2014-07-24"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infection","Cardiovascular Disease","Inflammation","HIV Infections"],"interventions":[{"type":"DRUG","name":"Maraviroc","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Maraviroc","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the potentially beneficial aspects of CCR5 inhibition on inflammation and endothelial function as measured by brachial artery reactivity in antiretroviral treated HIV patients with an undetectable viral load.","primaryOutcome":{"measure":"Percent Change in FMD","timeFrame":"Baseline, 24 weeks","effectByArm":[{"arm":"Maraviroc","deltaMin":0.57,"sd":2.1},{"arm":"Placebo","deltaMin":-0.05,"sd":2.1}],"pValues":[{"comp":"OG000","p":"0.17"},{"comp":"OG001","p":"0.90"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":26},"commonTop":[]}}